VERIGRAFT Advances First Potential Curative Treatment for CVI into Pivotal Phase II/III Trial
--------------------------------------------------------------------
Source: The Korea Herald
Published: 2026-03-25 21:40 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, Law & Courts, Crime & Justice
--------------------------------------------------------------------
Snippet:
GOTHENBURG, Sweden, March 25, 2026 /PRNewswire/ -- VERIGRAFT, a Swedish clinical-stage biotechnology company pioneering personalized, fully biological therapies, today announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insufficiency (CVI), supported by USD 10 million from existing investors.
--------------------------------------------------------------------